首站-论文投稿智能助手
典型文献
Association between 15 known or potential breast cancersusceptibility genes and breast cancer risks in Chinese women
文献摘要:
Objective: There are many hereditary breast cancer patients in China, and multigene panel testing has been a new paradigm of genetic testing for these patients and their relatives. However, the magnitude of breast cancer risks related to multiple breast cancer susceptibility genes are largely unknown in Chinese women.Methods: We screened pathogenic variants in 15 established or potential breast cancer susceptibility genes from 8,067 consecutive Chinese female breast cancer patients and 13,129 Chinese cancer-free female controls. These breast cancer patients were unselected for age at diagnosis or family history. Results: We found that pathogenic variants in TP53 [odds ratio (OR): 16.9, 95% confidence interval (CI): 5.2–55.2]; BRCA2 (OR: 10.4, 95% CI: 7.6–14.2); BRCA1 (OR: 9.7, 95% CI: 6.3–14.8); and PALB2 (OR: 5.2, 95% CI: 3.0–8.8) were associated with a high risk of breast cancer. ATM, BARD1, CHEK2, and RAD51D were associated with a moderate risk of breast cancer with ORs ranging from 2-fold to 4-fold. In contrast, pathogenic variants of NBN, RAD50, BRIP1, and RAD51C were not associated with increased risk of breast cancer in Chinese women. The pathogenic variants of PTEN, CDH1, and STK11 were very rare, so they had a limited contribution to Chinese breast cancer. Patients with pathogenic variants of TP53, BRCA1, BRCA2, and PALB2 more often had early-onset breast cancer, bilateral breast cancer, and a family history of breast cancer and/or any cancer. Conclusions: This study provided breast cancer risk assessment data for multiple genes in Chinese women, which is useful for genetic testing and clinical management of Chinese hereditary breast cancer.
文献关键词:
作者姓名:
Fenfen Fu;Dongjie Zhang;Li Hu;Senthil Sundaram;Dingge Ying;Ying Zhang;Shuna Fu;Juan Zhang;Lu Yao;Ye Xu;Yuntao Xie
作者机构:
Department of Breast Surgery,Peking University International Hospital,Beijing 102206,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Familial&Hereditary Cancer Center,Peking University Cancer Hospital&Institute,Beijing 100142,China;Prenetics Limited,Hong Kong 999077,China;Beijing CircleDNA Gene Technology Co.,Ltd.,Beijing 100020,China
引用格式:
[1]Fenfen Fu;Dongjie Zhang;Li Hu;Senthil Sundaram;Dingge Ying;Ying Zhang;Shuna Fu;Juan Zhang;Lu Yao;Ye Xu;Yuntao Xie-.Association between 15 known or potential breast cancersusceptibility genes and breast cancer risks in Chinese women)[J].癌症生物学与医学(英文版),2022(02):253-262
A类:
cancersusceptibility,multigene,RAD51D,RAD51C
B类:
Association,between,potential,breast,genes,risks,Chinese,women,Objective,There,many,hereditary,patients,China,panel,testing,has,been,new,paradigm,genetic,these,their,relatives,However,magnitude,related,multiple,largely,unknown,Methods,We,screened,pathogenic,variants,established,from,consecutive,female,free,controls,These,were,unselected,diagnosis,family,history,Results,found,that,TP53,odds,ratio,confidence,interval,BRCA2,BRCA1,PALB2,associated,high,ATM,BARD1,CHEK2,moderate,ORs,ranging,fold,In,contrast,NBN,RAD50,BRIP1,not,increased,PTEN,CDH1,STK11,very,rare,they,had,limited,contribution,Patients,more,often,early,onset,bilateral,Conclusions,This,study,provided,assessment,data,which,useful,clinical,management
AB值:
0.455325
相似文献
Characteristics of TP53 germline variants and their correlations with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patients
Panwen Tian;Xiaoyan Zhang;Sheng Yang;Yu Fang;Hongling Yuan;Wei Li;Honglin Zhu;Fangping Zhao;Jinlei Ding;Yunshu Zhu;Sizhen Wang;Guochen Sun;Hongbin Ni;Tonghui Ma;Ting Lei-Department of Respiratory and Critical Care Medicine,Lung Cancer Treatment Center,West China Hospital,Sichuan University,Chengdu,Sichuan 610041,China;Department of Translational Medicine,Genetron Health(Beijing)Technology,Co.Ltd.,Beijing 102206,China;National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100005,China;Department of Thoracic Surgery,The Second Hospital of Dalian Medical University,Dalian,Liaoning 116023,China;Genetron Health(Beijing)Technology,Co.Ltd.,Beijing 102206,China;Department of Neurosurgery,The First Medical Center of PLA General Hospital,Beijing 100853,China;Department of Neurosurgery,Nanjing Drum Tower Hospital(Nanjing Gulou Yi Yuan),The Affiliated Hospital of Nanjing University Medical School,Nanjing 210008,China
Sex disparity of lung cancer risk in non-smokers: a multicenter population-based prospective study based on China National Lung Cancer Screening Program
Wu Zheng;Tan Fengwei;Yang Zhuoyu;Wang Fei;Cao Wei;Qin Chao;Dong Xuesi;Zheng Yadi;Luo Zilin;Zhao Liang;Yu Yiwen;Xu Yongjie;Ren Jiansong;Shi Jufang;Chen Hongda;Li Jiang;Tang Wei;Shen Sipeng;Wu Ning;Chen Wanqing;Li Ni;He Jie-Office of Cancer Screening, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;Key Laboratory of Cancer Data Science, Chinese Academy of Medical Sciences, Beijing 100021, China;Department of Thoracic Surgery, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;PET-CT Center, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China;Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu 211166, China;Department of Diagnostic Radiology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer
Dan Lyu;Binliang Liu;Bo Lan;Xiaoying Sun;Lixi Li;Jingtong Zhai;Haili Qian;Fei Ma-Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Breast Cancer Medical Oncology,Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University,Changsha 410013,China;Department of Medical Oncology,Cancer Hospital of Huanxing Chaoyang District,Beijing 100122,China;State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China
Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
Binghe Xu;Huiping Li;Zefei Jiang;Lin Gu;Jinhai Tang;Hui Xie;Yueyin Pan;Yunjiang Liu;Shude Cui;Xiaojia Wang;Li Cai;Yiqiong Zhang;Huadong Zhao;Zhimin Shao-Department of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Breast Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Breast Cancer,the Fifth Medical Center of Chinese PLA General Hospital,Beijing 100071,China;Department of Breast Cancer,Tianjin Cancer Institute and Hospital,Tianjin 300060,China;Department of Breast Cancer,Jiangsu Provincial Hospital,Nanjing 210029,China;Department of Breast Cancer,the First Affiliated Hospital of China University of Science and Technology,Hefei 230001,China;Department of Breast Cancer,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Breast Cancer,Henan Cancer Hospital,Zhengzhou 450008,China;Department of Breast Cancer,Zhejiang Cancer Hospital,Hangzhou 310012,China;Department of Breast Cancer,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Clinical Development,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Statistics,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Breast Surgery,Shanghai Cancer Center/Cancer Institute,Shanghai Medical College,Fudan University,Shanghai 200032,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。